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Abstract
Multiple sclerosis (MS) is a demyelinating disease of unknown origin that affects the central nervous system of an estimated
400,000 Americans. GBV-C or hepatitis G is a flavivirus that is found in the serum of 1–2% of blood donors. It was originally
associated with hepatitis, but is now believed to be a relatively non-pathogenic lymphotropic virus. Fifty frozen specimens
from the brains of deceased persons affected by MS were obtained along with 15 normal control brain specimens. RNA was
extracted and ribosomal RNAs were depleted before sequencing on the Illumina GAII. These 36 bp reads were compared
with a non-redundant database derived from the 600,000+ viral sequences in GenBank organized into 4080 taxa. An
individual read successfully aligned to the viral database was considered to be a ‘‘hit’’. Normalized MS specimen hit rates for
each viral taxon were compared to the distribution of hits in the normal controls. Seventeen MS and 11 control brain
extracts were sequenced, yielding 4–10 million sequences (‘‘reads’’) each. Over-representation of sequence from at least one
of 12 viral taxa was observed in 7 of the 17 MS samples. Sequences resembling other viruses previously implicated in the
pathogenesis of MS were not significantly enriched in any of the diseased brain specimens. Sequences from GB virus C
(GBV-C), a flavivirus not previously isolated from brain, were enriched in one of the MS samples. GBV-C in this brain
specimen was confirmed by specific amplification in this single MS brain specimen, but not in the 30 other MS brain
samples available. The entire 9.4 kb sequence of this GBV-C isolate is reported here. This study shows the feasibility of deep
sequencing for the detection of occult viral infections in the brains of deceased persons with MS. The first isolation of GBV-C
from human brain is reported here.
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Introduction
Multiple sclerosis (MS) is a chronic demyelinating disease of
unknown cause, which affects the brain and spinal cord of about
400,000 individuals in the U.S. A number of viral infections of the
CNS can lead to demyelination, including distemper (dogs),
measles (SSPE, humans), and influenza (humans). [1] Viruses have
long been suspected as causative agents in MS based on the
epidemiology of the disease including geographic patterns, isolated
outbreaks, and migration studies. [2,3,4,5] Novel viruses that
cause human disease continue to be discovered using molecular
techniques including hepatitis C (1989), corona virus NL63 (2004),
bocavirus (2005), and rhinovirus C group(2007). [6,7,8,9] New
human polyoma and arenaviruses, identified by high-throughput
or ‘‘deep’’ sequencing of pathologic specimens, were recently
discovered as causes of serious human diseases(2008). [10,11]
To date most studies into the possible viral etiology of MS
have focused on human DNA viruses. Unfortunately, because
DNA viruses can become latent or quiescent within the CNS, it
is difficult to discern whether latent, commensal viruses
associated with MS lesions (e.g. HHV-6 and EBV) are causative
or just opportunistic (i.e. ‘‘along for the ride’’). To avoid the
identification of latent viruses that are not transcriptionally
active, the present investigation focused on viral RNA – both
genomic (from RNA viruses) and message (from either RNA or
DNA viruses).
Deep sequencing offers a new approach for the discovery of
pathogens. In contrast to PCR, this approach allows a relatively
unbiased survey of nucleic acid sequences found within a sample.
Deep sequencing provides millions of short sequences less than
100 bp in length. The completion of the Human Genome Project
allows subtraction of human sequences from the dataset resulting
in a large number of plausibly-nonhuman sequences that can then
be compared to existing databases such as GenBank. This
technique was recently employed to discover novel picornaviruses
linked to respiratory illness and diarrhea in children. [12,13]
PLoS ONE | www.plosone.org 1 March 2012 | Volume 7 | Issue 3 | e31886GB virus-C (GBV-C or hepatitis G virus) is a human flavivirus
originally isolated from a surgeon (with the initials G.B.) who was
experiencing acute hepatitis. [14] The GB viruses are approxi-
mately 10 kb in size and are most closely related to hepatitis C
virus. Other flaviviruses include dengue viruses, West Nile virus,
yellow fever virus, and the tick-borne encephalitis viruses. In
addition to humans, GBV-A and GBV-B infect monkeys, GBV-C
infects chimpanzees. The recently described GBV-D infects only
bats. [15,16] Animal inoculations suggested that GBV-C might be
a cause of hepatitis, but subsequent human observations did not
confirm this. GBV-C is known to be lymphotropic and has been
found in human serum, muscle, lymphoid tissue, spleen, kidney
and liver, but not brain (0 of 8 specimens) or spinal fluid (0 of 17
specimens). [17,18,19] Surveys show that active viral replication
occurs in the blood in 1–2% of human blood donors while about
5% of the general population is seropositive. [20] Viral replication
can persist for years at high titer (up to 50 million copies per ml
blood). This virus is believed to be nonpathogenic, but has been
associated with non-Hodgkin’s lymphoma. [21,22,23] Resolution
of GBV-C infection is often accompanied by antibody production
against the envelope (E2) protein. GBV-C infection appears to
induce antibodies that cross-neutralize HIV, probably explaining
the observed survival benefit of persons infected with both viruses
over those with HIV alone. [24]
We report the results of deep sequencing of diseased brain tissue
(plaque) taken from deceased patients with multiple sclerosis. This
method identified one occult viral infection with GBV-C in a
patient who died with primary progressive MS.
Methods
Brain Specimens
One hundred mg pieces of cryopreserved white matter from MS
plaques or control specimens were obtained from the Human
Brain and Spinal Fluid Resource Center, West Los Angeles VA
Medical Center and from the Rocky Mountain MS Center,
University of Colorado, Denver. These specimens were collected
after death and were either fresh frozen or snap frozen in liquid
nitrogen. This research was submitted to the University of Utah
Health Sciences IRB and, since it was performed on deidentified
pathologic material, was found to be exempt from review and
oversight.
RNA Extraction and Quality Control
DNase treated RNA was extracted from the tissue sections using
Qiagen RNA-lipid kits (Valencia, CA) on dry ice, under laminar
airflow. Purified RNA was quantified on a Thermo Scientific
Nanodrop spectrophotometer (Waltham, MA). Samples with
absorbance (A260/A280) ratio ,1.8 were rejected and re-extracted.
Fifty ng of RNA from each sample was submitted the Huntsman
Cancer Institute (HCI) Microarray Core Facility lab for analysis
on an Agilent 2100 Bioanalyzer Nanochip (Agilent Technologies,
USA). The extracted RNA samples were evaluated for their
distribution of RNA sizes, their relative abundances, the height
and relative ratio of the 28S and 18S rRNA peaks, and for RNA
integrity (RIN) as determined by the Agilent software. Each
sample was evaluated by an experienced technician and then
independently by one of the investigators. Samples with an
unfavorable electrophoresis trace or RIN were not sequenced.
Ribosomal RNA Depletion
To enhance the detection of non-human sequences, RNA
samples that passed the quality control step above were subjected
to rRNA removal using the RiboMinus kit (Invitrogen Inc.,
Carlsbad, CA). Recovered RNA (post rRNA removal) was again
quantified and subjected to Bioanalyzer analysis.
Illumina GAII Sequencing
RNA samples that passed the RNA quality control were
submitted to the Huntsman Cancer Institute Microarray Core
Facility for reverse transcription, cDNA library preparation, and
high-throughput sequencing. Datasets of 36 bp sequences, or
reads, were obtained from each brain sample. Low complexity
(LZW compressibility .0.4) reads, reads with homopolymeric
stretches longer that 18 bases and those with Bustard quality scores
#5 in more than 13 positions were excluded from the analysis.
The remaining reads are defined as ‘‘high quality reads.’’ Reads
which perfectly matched UCSC build 18 of the human genome, as
judged by Bowtie alignments, were excluded from the analysis.
Weaker matches to mammalian rRNA transcripts were detected
and removed from the data set using MegaBLAST (word
size=12) with a database of 45S pre-rRNA and 28S sequences
(gis: 1261918 and 225637499). The remaining high quality,
nonhuman, nonribosomal reads were defined as ‘‘screened reads.’’
Comparative enrichment of viral sequence was then determined
using these filtered sequences (screened reads).
Virus-Like Sequence Filtering and Enrichment
A non-redundant database of viral sequences was built to
reduce noise from highly oversampled taxa in the public
databases. This nonredundant database is 98 megabases in size
organized into 4080 viral taxa. All viral sequence in GenBank was
obtained (more than 600,000 records). The longest sequence from
each viral taxa was extracted from the input sequence set and
placed in the non-redundant output set. All subsequences longer
than 23 bases in the input that were compared to the sequence
that was just extracted. Identities were removed from the input by
replacing the identical subsequence with X’s. The longest
remaining sequence, thus screened, was then extracted from the
input, placed in the non-redundant output and used to screen the
remaining input sequences. The process was repeated until no
unscreened subsequences longer than 49 bases remained in the
input. The resulting database, NR_ViroBank is available online
(http://fischer-lab.path.utah.edu/data/GBV-C).
MegaBLAST was used to align the brain sequences to
NR_ViroBank using a low-stringency protocol. A word size of
16 was used, sequence filtering was disabled, and sequence-virus
pairs with expect values #1.0 were considered in further analysis.
The hit-rate (HRT-S) of a sample to a viral taxon was calculated
using Equation 1 where the number of alignments to a given taxon
(AT-S) is normalized by the number of filtered nonribosomal
sequences obtained for the specimen (RS):
HRT{S~
AT{S
RS
The mean and standard deviation of the normalized hit rates in
the control specimens were determined for each viral taxon. The
distribution of control hits was examined for normality. Taxa with
non-normally distributed control hit rates were excluded from
further analysis. The hit rates of each individual MS sample were
then compared to the control hit-rate distribution for each taxon.
Using the python programming language and scipy, the
Bonferroni corrected Student’s t-Test was used to quantify the
statistical significance of any overrepresentations within each MS
sample. Cluster and Java Treeview were used to generate an
unsupervised cluster of significant sample-taxa p-value pairs.
[25,26]
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PCR primers were designed from 4 regions of the GBV-C
genome based on the deep sequencing results. Reverse transcrip-
tion was performed using independent forward and reverse gene
specific priming. Primers were selected from the 59-NTR, E2, and
NS3 gene regions based on Souza et. al. with modifications as
suggested by the deep sequencing results. [27] Primer sequences
(59-39) employed were:
N 59-NTR-1: AAGCCCCAGAAACCGACGCC,
TGAAGGGCGACGTGGACCGT
N 59-NTR-2: CGGCCAAAAGGTGGTGGATG,
GTRWCGGKCTCGGTTTAACG
N E2: TGGNTCWGCCAGYTGYACCAT, DTCYCG-
GATCTTGGTCATGG
N NS3: TCGGCWGARYTGTCGATGCA, ACGCCGCGHA-
CYTTTGCCCA
Quantitation of GBV-C was performed using the following (59-
NTR) primer and probe sequences:
N Forward: 59-GGCGACCGGCCAAAA-39 (nt 96–110)
N Reverse: 59-CTTAAGACCCACCTATAGTGGCTACC-39
(nt 163–188)
N Probe: 59-FAM-TGACCGGGATTTACGACCTAC-
CAACCCT-tamra-39 (nt 131–158)
SuperScriptH III One-Step RT-PCR System with PlatinumH
Taq DNA Polymerase (Invitrogen, Carlsbad, CA) was used with
running conditions: 50uC 20 min, 95uC 2 min, 40 cycles of 95uC
15 sec, 58uC one minute. A standard curve was generated using
log dilutions of synthetic standard GBV-C RNA (kindly provided
by the Stapleton laboratory at the University of Iowa).
Immunohistochemistry
Three anti-GBV-C antibody preparations and controls were
kindly provided by the Jack Stapleton laboratory at the University
of Iowa. These included pre- and post-immune rabbit polyclonal
antiserum against GBV-C E2 protein [24], mouse monoclonal
anti-E2 #7067 [24], and mouse monoclonal 1C4 [28], plus
control mouse IgG1 (Vector Laboratories, Burlingame, CA).
Frozen MS and control brain tissues were thawed and fixed in 4%
paraformaldehyde. Five micron paraffinized sections were used.
Antigen retrieval was performed (Vector product H-3300). The
tissues were penetrated with Triton-X and endogenous peroxidase
was quenched. Sections were blocked with 5% normal goat serum
(Vector product S-1000). Appropriate goat anti-rabbit or goat-
anti-mouse IgG secondary antibodies (Santa Cruz Biotechnology,
products sc-2004 and sc-2060) were diluted 1:500–1:000 as
recommended by the manufacturer. Signal was developed with
NovaRed (Vector product SK-4800).
Assembly of the GBV-C Isolate Sequence
Thirty-two specific primers to the MS-6 GBV-C isolate were
designed using the GAII sequences that were highly homologous
to known GBV-C isolates. Overlapping amplicons were
obtained using RT-PCR with freshly extracted total RNA from
sample 3840. Amplicons were TOPO-cloned and sequenced
using an ABI 3730 sequencer. The Sanger sequences were
processed and assembled using the phred, phrap and consed
programs using a known GBV-C scaffold (gi: 1666805). [29,30]
The GAII reads were added to this intermediate assembly using
consed.
Results
Brain Specimen Characteristics
Fifty frozen MS plaque and 15 control, undiseased brain
specimens were extracted. Among these, 17 MS and 11 control
brain specimens were selected for sequencing based on favorable
RNA quality profiles. These brain specimens were collected
between the years 1983 and 2004. They were kept frozen at 270
degrees until being subjected to RNA extraction in our laboratory.
Characteristics of the sequenced brain specimens are shown in
Table S1. The post-mortem intervals between the MS and control
specimens were similar: 12.962.2 vs. 11.561.6 hours (p=0.64 by
unpaired t-testing). The MS subjects were younger than the
controls at the time of specimen collection: a median of 55 vs. 69
years, (p=0.01 by unpaired t-testing). The proportion of
specimens obtained from each of the two brain banks was similar
between the MS and control groups (p=0.7 by Fisher’s Exact test).
The 17 sequenced MS specimens came from deceased patients
that carried the diagnoses of primary progressive MS (3), chronic
progressive multiple sclerosis (5), secondary progressive MS (5),
relapsing-remitting MS (2), or multiple sclerosis, subtype not
specified (2).
Deep Sequencing Results
High-throughput sequencing on the Illumina GAII yielded 4–
24 million 36 bp sequences (‘‘reads’’) from each of the 28 brain
specimens (17 MS, 11 normal controls). These reads are
designated as ‘‘high quality reads’’ in Table S1. These sequences
represent cellular RNA, not DNA, and therefore correspond either
to viral genomes or to actively transcribed genes, both human and
nonhuman, present in the specimen. Human and ribosomal reads
were subtracted from the dataset, providing 0.9–7.4 million
screened reads for analysis. There were no significant differences
in the number of high quality reads or screened reads between the
MS and control specimens (p.0.5 by Mann-Whitney testing).
Identification of Viral Candidates for Further Analysis
Viral alignments were performed on the sequences derived from
each of the MS and control brain specimens. Hit rates were
calculated for each taxon represented in the nonredundant viral
database (N=4080). The mean and standard deviation of the hit
rates in the control specimens were determined for each taxon.
Only 109 out of 7947 (1.4%) viral taxa showed a non-normal
distribution of control hit rates. These were removed from further
consideration. Bacteriophage and plant virus taxa were excluded
from further analysis due to less biologic significance compared
with human and animal viruses. Retroviruses were reserved for
later analysis due to the ubiquitous expression of human
endogenous retroviruses (HERVS) in human specimens. Hits
were observed to 2153 remaining taxa. The hit rates to each taxon
for each MS sample were then compared to the control hit rate
distribution for that taxon. Student’s t-Test corrected for multiple
comparisons using the Bonferroni method was used to quantify the
statistical significance of any apparent over-representation ob-
served in the MS samples. The 12 taxa with a least one MS sample
with a over-representation more significant than p=0.05 were
placed into a hierarchical cluster (Figure 1). Over-representation in
at least one taxon was observed in 7 of the 17 MS samples.
Candidate Follow Up and Viral Sequence Recovery From
Specimens
The 36 bp reads from the Illumina sequencing are not likely to
identify any viruses unambiguously. Overrepresented viral taxa
(shown in Figure 1) had all the deep sequencing reads from the
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sequences for the taxon of interest. The reads were then joined
into contiguous regions (contigs) using SSAKE, a short read
assembler. [31] Contigs generated by SSAKE were then aligned
back to the taxon specific database. These newly assembled contigs
were then aligned to both host and taxon specific viral databases
again. Contigs that had improved alignment quality (compared to
single reads) to the candidate viral sequences and worse alignment
to human sequences were used to design primers for virus specific
RT-PCR. The results of this analysis are shown in Table 1. This
strategy identified GBV-C as a promising candidate for PCR
follow up in a single MS brain sample.
Lack of Overrepresentation of RNA from Viruses
Previously Implicated in MS
Table 2 shows the analysis of deep sequencing results for viral
taxa previously implicated in the pathogenesis of MS. Overall, the
MS specimen hit rate was relatively high for the human
herpesviruses compared to other viral taxa, probably due to the
detection of RNA expressed during latency. It is also possible that
these higher hit rates are driven by short sequences derived from
abundant human transcripts that align to the herpesvirus taxa.
However, none of the human herpesvirus nor measles virus hit rates
differed significantly between the MS and control distributions.
Confirmation of GBV-C in One MS Brain Specimen
One subject who died with primary-progressive MS had .1000
36 bp sequences detected that mapped to GBV-C virus (hepatitis
G), a human flavivirus not known to cause any persistent disease
and never before detected in human brain. [14,17,18] This brain
specimen was investigated further. An initial attempt to amplify
GBV-C from this specimen using published primers was
unsuccessful, later determined to be due to sequence variation of
the isolate. [27] PCR primers for 3 viral regions (59-NTR, E2, and
NS3) were designed from the contigs assembled from the Illumina
sequencing data on this particular subject. RT-PCR amplification
of these regions revealed amplicons of the expected sizes,
approximately 300 bp (Figure 2). Sequencing of the amplicons
showed 96–99% identity to .100 known GBV-C sequences.
Quantitative rtPCR of this brain sample showed that there were
between 1.7610
6 and 2.4610
6 viral genome copies per gram of
tissue. Interrogation of CSF from this subject showed 1.1610
6
viral genome copies/ml. Blood from this subject was not available
for analysis. Anti-GBV-C antibodies were not detected in CSF
from this subject (personal communication from Dr. Jack
Stapleton).
Attempts to Detect GBV-C in Other MS and Control
Specimens
Specific RT-PCR amplification of 31 affected (MS) and 23
unaffected (control) brain samples was performed with each of the
3 GBV-C primer sets testing for both positive and negative strand
viral RNA, using the existing GBV-C positive sample as a positive
control. Both strands of GBV-C RNA were detected only in
subject MS-6, both before and after ribosomal removal, and not in
any of the other 53 brain RNA specimens studied. Twenty MS
and seven control CSF samples were interrogated with 3 separate
GBV-C specific primers (NTR-1, E2, and NS3). The MS-6 CSF
sample was used as a positive control. GBV-C was amplified from
none of these other 27 CSF samples.
Full Sequence of the GBV-C Isolate
The recovered sequence of GBV-C UU1 contained a open
reading frame of 2842 codons, containing the structural and
Figure 1. Representational Analysis. Virus-like sequences overrepresented in MS brain specimens compared with controls are displayed.
Bonferroni corrected p-values beginning with 0.05 are displayed. Each row (labeled, N=64) represents an overrepresented viral taxon. Each column
(N=17) represents a different MS brain specimen. The shaded yellow boxes represent significant hits. The GBV-C sequences confirmed by PCR in one
of the specimens is circled in red.
doi:10.1371/journal.pone.0031886.g001
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compared to 24 other genomic length isolates in GenBank. The
isolate most similar (89.7%, nucleotide identity over the genome)
to GBV-C UU1 was the East African isolate GBV-C (EA)
(gi:1666805). [32] At the amino acid level the viral polyprotein was
97.7% identical to GBV-C (EA) (64 coding differences). The
sequence of GBV-C UU1 has been deposited with GenBank (GB
JN127373).
Immunohistochemistry
Immunohistochemistry with controls was attempted on GBV-C
infected, MS afflicted brain (MS-6); other MS brain specimens
where GBV-C was not detected by PCR; and several normal brain
controls. Some anti-GBV-C dependent staining of neuronal
cytoplasm was observed in both infected and uninfected brain
sections with the polyclonal rabbit anti-GBV-C preparation. The
monoclonal Ab preparations did not specifically detect GBV-C in
any of the human brain tissues examined, including that from MS-
6 (shown by molecular methods to contain GBV-C RNA).
Discussion
This work demonstrates the feasibility of deep sequencing for
the detection of occult viral infections in brain tissue. This method
revealed several viral candidates. The presence of one of these
candidates, GBV-C, was confirmed in the brain of one of the
subjects who suffered and died with progressive MS. This virus has
never been detected before in human brain tissue. It’s relationship
with the underlying disease, primary progressive multiple sclerosis,
in this single person is not clear. RNA sequences from other
viruses previously implicated in the pathogenesis of MS including
Table 1. Virus-like sequence short read assembly.
Viral Taxon
Viral Family p-value
1 Longest Aligned Contig
2 # MS Brain Specimens
3 Result
Simian adenovirus-6
Adenoviridae
.04 ,36 bp 1 not confirmed as viral sequence
4
Border disease virus
Flaviviridae
9610
24 ,36 bp 1 not confirmed as viral sequence
4
Psittacid herpesvirus 1
Herpesviridae
6610
212 ,36 bp 2 not confirmed as viral sequence
4
Gallid herpesvirus 1
Herpesviridae
6610
25 ,36 bp 3 not confirmed as viral sequence
4
Hepatitis B virus
Hepadnaviridae
2610
29 60 bp 5 human sequence
5
Porcine teschovirus
Picornaviridae
2610
23 ,36 bp 1 not confirmed as viral sequence
4
Ectromelia virus
Poxviridae
4610
25 ,36 bp 3 not confirmed as viral sequence
4
Ostreid herpesvirus 1
Maculoverpesviridae
4610
26 ,36 bp 2 not confirmed as viral sequence
4
Bovine herpesvirus 1
Herpesviridae
9610
24 ,36 bp 1 not confirmed as viral sequence
4
GBV-C
Flaviviridae
9610
29 106 bp 1 assembled, confirmed by PCR
Foot and Mouth Disease virus
Picornaviridae
4610
22 ,36 bp 1 not confirmed as viral sequence
4
Bovine adenovirus D
Adenoviridae
5610
24 ,36 bp 3 not confirmed as viral sequence
4
1students t-test (minimum value) corrected for multiple comparisons by the Bonferroni method.
2maximum length of all the assembled reads that aligned to the indicated virus.
3number of MS brain specimens that had reads with significant homology (MegaBlast Expect #0.1) to the indicated viral sequences.
4The assembly of short reads did not improve alignment with the specified viral sequences.
5Assembly revealed homology to human mitochondrial and host integration sites.
doi:10.1371/journal.pone.0031886.t001
Table 2. Deep sequencing results for viruses previously
implicated in MS pathogenesis.
Viral Taxon
1
MS Specimen Hit
Rate Range
2
Control
Hit Rate
3
t-Test
p-value
4
Cytomegalovirus 369–543 540626 0.37
Human herpesvirus-6 331–447 40868 0.062
Epstein-Barr virus 478–794 693643 0.20
Measles virus 13.9–25.7 15.660. 68 *
1Viral taxa are defined as sequences in GenBank below the level of family. This
includes sequences identified as belonging to genus or species or subspecies
(strain). It also includes sequences not assigned to a specific species or genus.
2The MS Specimen Hit Rate is defined as the number of hits for a given taxon or
species divided by the number of total non-ribosomal reads. This method is
used to normalize these values between specimens. The range of hit rates
among the 17 sequenced MS brain specimens is displayed.
3The control specimen hit rates for each viral taxon are expressed as the mean
6 SEM among the 8 control specimens.
4Null hypothesis=the tested MS specimen falls within the expected distribution
of control samples. Values provided are two-tailed. The minimum p-value
among all 17 tested MS samples is shown.
*The p-value could not be calculated because the control hit rates are not
normally distributed.
doi:10.1371/journal.pone.0031886.t002
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overrepresented in the diseased brain specimens compared with
controls.
GBV-C or hepatitis G virus is currently believed to be
nonpathogenic. However, this virus was originally isolated from
a human who was suffering from acute hepatitis. [33,34] Prior
attempts to isolate GBV-C from the brain in infected subjects were
unsuccessful. [18] Other flaviviruses certainly do infect the human
central nervous system including West Nile virus, dengue [35,36],
tickborne encephalitis viruses, and Japanese encephalitis virus.
Even hepatitis C virus has been isolated from diseased brain in a
patient with fatal demyelinating disease. [37] The epidemiology of
GBV-C infection is similar to that of MS itself where infection/
disease is rare in children and much more common in women of
childbearing age. [38] GBV-C is, in part, sexually transmitted.
[39,40,41] The sex predominance of GBV-C infection is about 2:1
women:men, again similar to MS. [42]
The presence of both positive (RNA genome) and negative
(replication intermediate) strand flaviviral RNA in MS-6 suggests
that the virus was actively replicating in the brain of this subject.
Active replication is also supported by this subject’s pathology
report showing ‘‘active plaques’’ with a perivascular lymphocytic
infiltrate (data not shown). The clinical history revealed onset of
primary progressive MS beginning at age 44 in an otherwise
healthy Caucasian woman. The disease was relentless causing the
subject to use a wheelchair by age 55 and to become bed bound at
age 60. Active replication GBV-C in the brain of MS-6 is also
supported by the relatively high titer of virus observed in both
tissue and CSF (1–2 million copies per ml) and the absence of anti-
GBV-C antibodies in the CSF.
Actively replicating GBV-C in this subject’s brain may or may
not be causal. GBV-C may be found in the blood of humans for
years after acute infection and it may be present at high titer – in
the range of 10
8 copies per milliliter of blood. [14,20] Resolution
of GBV-C viremia usually coincides with the development of
antibodies to the virus. GBV-C replicates primarily in peripheral
blood mononuclear cells, including lymphocytes, so its presence in
the brain of subject MS-6 may simply reflect penetration of the
Figure 2. Amplification of GBV-C RNA from the brain of MS-afflicted subject MS-6. Following the failure of published primers to amplify
sequences in this specimen, specific primers were constructed based on the sequences of specific reads obtained from the Illumina GAII sequencing
of this specimen. [27] A. Four regions of the GBV-C genome were selected for amplification including 2 sites in the 59 non-translated region, the E2
(envelope protein) gene, and NS3 (non-structural). B. Amplicons were derived from each of these primer sets, including + (genome) and 2
(replication intermediate) strands. Sequencing of 3 of these amplicons spanning 906 bp revealed identity with .100 published GBV-C isolates,
indicating that this subject had a novel strain of GBV-C in her brain tissue which appeared to be replicating at the time of her death.
doi:10.1371/journal.pone.0031886.g002
Figure 3. Assembly of GBV-C sequences from the deep sequencing reads. Sanger sequencing results from brain specimen MS-6 are shown
in green. Deep sequencing reads from subject MS-6 that aligned perfectly (36/36 bp matches) to the GBV-C genome are displayed in orange.
doi:10.1371/journal.pone.0031886.g003
Deep Sequencing of MS Brain Specimens
PLoS ONE | www.plosone.org 6 March 2012 | Volume 7 | Issue 3 | e31886damaged blood-brain barrier by serum or virus-infected lympho-
cytes. [18] On the other hand, persistent GBV-C infection of the
brain might have manifestations not previously described, such as
progressive demyelination. Animal studies demonstrate that viral
infections of the CNS can result in a demyelinating disease that is
similar to MS. [43,44,45,46,47] The failure to specifically detect
GBV-C by immunohistochemistry in brain sections from subject
MS-6 was disappointing. This may be due to a relative absence of
viral antigen in these tissues or the lack of suitable reagents for the
detection of GBV-C antigen in fixed, paraffinized tissue. In any
case, the lack of detectable GBV-C RNA from 30 other MS brain
specimens suggests that this virus will not be isolated frequently
from the brains of MS patients.
Deep sequencing is a powerful tool that has revealed new
pathogens. This report shows the feasibility of this technique for
the study of brain tissues affected by MS. A novel isolate of GBV-
C was identified here in this manner. The presence of GBV-C in
this brain specimen was confirmed by designing PCR primers
from the sequencing results. The deep sequencing analysis in this
study was based on the early Illumina GAII technology and
limited by read length (36-base pairs) and sequencing from only a
single end of the library inserts. The investigators believe that
further improvements in sequencing technologies, such as longer
reads and perhaps paired-end strategies, will significantly simplify
the bioinformatics required for future clinical viral metagenomic
studies.
Supporting Information
Table S1 Demographic, sequencing, and disease char-
acteristics of the sequenced MS and control brain
specimens. The source, age, sex, year of collection, post-mortem
interval, and diseases associated with each specimen used for this
study is shown here, along with the number of reads obtained.
(DOC)
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